FDA Rejects EPIX Appeal To Avoid New Trials
On Monday, the U.S. Food and Drug Administration denied an appeal from drug maker EPIX Pharmaceuticals Inc. to avoid a second round of trials for Vasovist, an injectible product already approved...To view the full article, register now.
Already a subscriber? Click here to view full article